D. Boral Capital reaffirmed their buy rating on shares of VolitionRx (NYSE:VNRX - Free Report) in a research report sent to investors on Wednesday,Benzinga reports. D. Boral Capital currently has a $5.00 price target on the stock.
VNRX has been the topic of a number of other reports. Benchmark reissued a "hold" rating on shares of VolitionRx in a research report on Friday, November 22nd. StockNews.com started coverage on shares of VolitionRx in a research report on Wednesday. They set a "sell" rating on the stock.
Check Out Our Latest Analysis on VNRX
VolitionRx Trading Down 3.6 %
Shares of VNRX traded down $0.02 on Wednesday, reaching $0.56. The company's stock had a trading volume of 40,502 shares, compared to its average volume of 178,866. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.02. The stock has a market capitalization of $51.99 million, a PE ratio of -1.56 and a beta of 1.09. The firm has a fifty day moving average of $0.61 and a 200-day moving average of $0.65.
Institutional Trading of VolitionRx
Hedge funds and other institutional investors have recently bought and sold shares of the company. Two Sigma Securities LLC bought a new position in shares of VolitionRx in the fourth quarter worth $29,000. Millennium Management LLC bought a new position in VolitionRx in the 4th quarter worth about $36,000. Northern Trust Corp raised its holdings in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after acquiring an additional 28,579 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company's stock valued at $439,000 after acquiring an additional 95,900 shares during the last quarter. Finally, Lagoda Investment Management L.P. grew its holdings in shares of VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock worth $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Institutional investors own 8.09% of the company's stock.
About VolitionRx
(
Get Free Report)
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Read More
Before you consider VolitionRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VolitionRx wasn't on the list.
While VolitionRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
